Skip to content
Dx

ICD-10-CM 2027 diagnosis code

QA1.792Li Fraumeni syndrome

✓ Billable / specificNew for 2027POA exempt

QA1.792 is a valid, billable ICD-10-CM code for li fraumeni syndrome. It can be reported on claims for dates of service from October 1, 2026 – September 30, 2027.

Code last changed in FY2027 (effective October 1, 2026). Source: official FY2027 ICD-10-CM release from CDC/NCHS and CMS. Page updated September 29, 2026. About our data

About QA1.792

QA1.792 is the ICD-10-CM diagnosis code for Li Fraumeni syndrome. It belongs to category QA1 (genetic disorders associated with neoplasms, not elsewhere classified), block QA0-QA1 (genetic disorders, not elsewhere classified) and chapter 17 (congenital malformations, deformations, chromosomal abnormalities, and genetic disorders). It is billable, so it can be reported on its own for dates of service from October 1, 2026 through September 30, 2027.

Within QA1.79 (other inherited neoplasm predisposition syndrome of multiple systems), QA1.792 is specifically for Li Fraumeni syndrome. Related codes cover familial cancer syndrome with pathogenic BRCA1 mutation (QA1.790), familial cancer syndrome with pathogenic BRCA2 mutation (QA1.791) and other inherited neoplasm predisposition syndrome of multiple systems (QA1.798).

It is not a CC or MCC, so as a secondary diagnosis it doesn't change the MS-DRG severity level.

In MS-DRG v44.0, it is part of the grouping logic for DRG 951 (Other Factors Influencing Health Status, relative weight 0.5577), in MDC 23 (Factors Influencing Health Status and Other Contacts with Health Services), as a principal or secondary diagnosis. The DRG a claim lands in depends on the principal diagnosis, procedures and any CC/MCC secondary diagnoses.

It is exempt from present-on-admission (POA) reporting, so no POA indicator is required.

It was added in FY2027, effective October 1, 2026.

Notes that apply from higher levels

Instructions written at a parent level also apply to QA1.792.

› From QA1 Genetic disorders associated with neoplasms, not elsewhere classified
Excludes2
  • multiple endocrine neoplasia [MEN] syndromes (E31.2-)
Code also
  • , if applicable, any associated conditions, such as:
  • genetic susceptibility to malignant neoplasm by site (Z15.0-)
  • malignant neoplasms (C00.0-C96.9)
  • personal history of malignant neoplasm (Z85.-)

Broader instructions also apply from Chapter 17: Congenital malformations, deformations, chromosomal abnormalities, and genetic disorders.

Alphabetic index entries

1 entries

Terms in the official ICD-10-CM index that lead to QA1.792.

MS-DRG v44.0 grouping

All DRGs →

Inpatient MS-DRGs this diagnosis can group to, as the principal or a secondary diagnosis, depending on the rest of the claim.

MDC 23 · Factors Influencing Health Status and Other Contacts with Health Services

Code history

  1. 2016
  2. 2017
  3. 2018
  4. 2019
  5. 2020
  6. 2021
  7. 2022
  8. 2023
  9. 2024
  10. 2025
  11. 2026
  12. 2027
  • FY2027 (effective 10/1/2026): Added

Common questions about QA1.792

Is QA1.792 billable?

Yes. QA1.792 is a billable/specific ICD-10-CM code valid for FY2027 (October 1, 2026 – September 30, 2027).

Can QA1.792 be used as a principal diagnosis?

Yes. The Medicare Code Editor doesn't restrict QA1.792 as a principal diagnosis.

Is QA1.792 a CC or MCC?

No. QA1.792 is neither a CC nor an MCC under MS-DRG v44.0.

What DRG does QA1.792 group to?

QA1.792 is used in the MS-DRG v44.0 logic for MS-DRG 951 (Other Factors Influencing Health Status). Which one applies depends on whether it is the principal diagnosis and on the rest of the claim.

Did QA1.792 change for 2027?

Yes. For FY2027 (effective October 1, 2026) it was added to the code set.